Modality
mRNA
MOA
CDK2i
Target
C5
Pathway
T-cell
HS
Development Pipeline
Preclinical
Dec 2022
→ Dec 2026
PreclinicalCurrent
NCT03218944
1,630 pts·HS
2022-12→2026-12·Completed
1,630 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-12-118mo awayInterim· HS
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
Preclinical
Complet…
Catalysts
Interim
2026-12-11 · 8mo away
HS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03218944 | Preclinical | HS | Completed | 1630 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Mavuglumide | Bayer | Approved | GLP-1R |